Bristol-Myers Squibb Company (BMY)
| Market Cap | 138.21B +43.9% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 14.73 |
| Forward PE | 10.42 |
| Dividend | $2.52 (3.73%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 7,694,163 |
| Open | 66.82 |
| Previous Close | 66.92 |
| Day's Range | 66.75 - 67.73 |
| 52-Week Range | 42.52 - 68.64 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 66.21 (-2.14%) |
| Earnings Date | Jul 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $66.21, which is a decrease of -2.14% from the latest price.
News
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday...
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
US FDA approves Bristol Myers' blood cancer treatment
The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the he...
Lawsuit against Bristol Myers over delayed cancer drug is revived
A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutic...
Bristol Myers to build $2.3 billion manufacturing site in Houston
Drugmaker Bristol Myers Squibb on Monday said it will spend about $2.3 billion to build a new manufacturing facility in Houston, Texas, part of a previously announced $40 billion commitment to inves...
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas.
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a moot...
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Astra Buying Bristol Makes No Sense, Fazeli Says
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers.
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the...
AstraZeneca holds talks with US cancer drug developer in $400bn merger
Bristol Myers Squibb tie-up would be one of biggest-ever pharma deals and create world's fourth-largest drugmaker
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billi...
Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?
AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks
If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal. If completed, a combined company could be valued at roughly roughly $400 billion.
AstraZeneca shares tumble 7% after reported Bristol Myers talks
AstraZeneca shares tumbled 7% in early trading on Monday following reports of talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the large...